BACKGROUND: Venous thromboembolism is a well-known complication of malignancy.
The Khorana Risk Score (KRS) utilizes the type of cancer, blood counts, and body mass …

Introduction: Khorana score (KS) stratifies patients into low, intermediate, and high risk
groups for venous thromboembolism (VTE). We examined the generalizability of the KS to …

Background Oncology guidelines suggest using the Khorana score to select ambulatory
cancer patients receiving chemotherapy for primary venous thromboembolism (VTE) …

Essentials• The Khorana score is validated for risk of venous thromboembolism (VTE) in
cancer outpatients.• We conducted a multicenter analysis of medically hospitalized cancer …

Background: Guidelines suggest the use of the Khorana score to select patients with solid
cancer receiving chemotherapy for thromboprophylaxis to prevent venous thromboembolism …

We aimed to evaluate the performance of the Khorana score in predicting venous
thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were …

Introduction: Although venous thromboembolism (VTE) is a well-known complication of
cancer, predicting and mitigating the risks associated with VTE related to cancer remain a …

The Khorana score is recommended for guiding primary venous thromboembolism (VTE)
prophylaxis in cancer patients, but its clinical utility overall and across cancer types remains …

Background Guidelines do not recommend that cancer outpatients receive
thromboprophylaxis unless at high venous thromboembolism (VTE) risk, with the Khorana …

Cancer patients with venous thromboembolism (VTE) are prone to poor prognoses. Thus,
we aimed to develop a nomogram to predict the risk of VTE in these patients. We …